当前位置： SCI文献检索 > BMC Psychiatry期刊下所有文献 > Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study.

Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study.

Abstract：

BACKGROUND:Escitalopram is licensed for use at doses up to 20 mg but is used clinically at higher doses. There is limited published data at higher doses and none in the treatment of Major Depressive Disorder (MDD). METHODS:This open-label, pilot study was designed to investigate the efficacy, safety and tolerability of escitalopram in doses up to 50 mg in MDD. It was conducted in 60 primary care patients with MDD who had not responded to adequate treatment with citalopram. Patients were treated with escalating doses of escitalopram up to 50 mg for up to 32 weeks until they achieved remission (Montgomery-Asberg Depression Rating Scale [MADRS] ≤ 8) or failed to tolerate the dose. RESULTS:Forty-two patients (70%) completed the study. Twenty-one patients (35%) achieved remission with 8 of the 21 patients (38%) needing the 50 mg dose to achieve remission. Median time to remission was 24 weeks and median dose in remission was 30 mg. No significant safety issues were identified although tolerability appeared to decline above a dose of 40 mg with 26% of patients unable to tolerate 50 mg. Twelve (20%) patients had adverse events leading to discontinuation. The most common adverse events were headache (35%), nausea, diarrhoea and nasopharyngitis (all 25%). Minor mean weight gain was found during the study, which did not appear to be dose-related. Half of the patients who completed the study chose to continue treatment with escitalopram rather than taper down the dose at 32 weeks. CONCLUSIONS:Dose escalation with escitalopram above 20 mg may have a useful role in the management of patients with MDD, although further studies are needed to confirm this finding. TRIAL REGISTRATION:ClinicalTrials.gov: NCT00785434.

journal_name

BMC Psychiatry

journal_title

BMC psychiatry

authors

Wade AG,Crawford GM,Yellowlees A

doi

10.1186/1471-244X-11-42

subject

Has Abstract

pub_date

2011-03-16 00:00:00

pages

42

issn

1471-244X

pii

1471-244X-11-42

journal_volume

11

pub_type

临床试验,杂志文章

相关文献

BMC Psychiatry文献大全